Duramycin |
| Catalog No.GD11220 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1391-36-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Evaluation of [68Ga]NODAGA-Duramycin as a positron emission tomography (PET) tracer of cell death for whole-body detection of chemotherapy-induced organ toxicity. Organ uptake is analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [68Ga]NODAGA-Duramycin. [68Ga]NODAGA-Duramycin PET/CT is successfully applied to non-invasively detect chemotherapy-induced organ toxicity with high sensitivity in mice[3].
[1]. Oliynyk I, et al. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. APMIS. 2010 Dec;118(12):982-90.
[2]. Huo L, et al. Insights into the Biosynthesis of Duramycin. Appl Environ Microbiol. 2017 Jan 17;83(3). pii: e02698-16.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *